Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The tumour suppressor p53 is a tetrameric protein that is phosphorylated in its BOX‐I transactivation domain by checkpoint kinase 2 (CHK2) in response to DNA damage. CHK2 cannot phosphorylate small peptide fragments of p53 containing the BOX‐I motif, indicating that undefined determinants in the p53 tetramer mediate CHK2 recognition. Two peptides derived from the DNA‐binding domain of p53 bind to CHK2 and stimulate phosphorylation of full‐length p53 at Thr 18 and Ser 20, thus identifying CHK2‐docking sites. CHK2 can be fully activated in trans by the two p53 DNA‐binding‐domain peptides, and can phosphorylate BOX‐I transactivation‐domain fragments of p53 at Thr 18 and Ser 20. Although CHK2 has a basal Ser 20 kinase activity that is predominantly activated towards Thr 18, CHK1 has constitutive Thr 18 kinase activity that is predominantly activated in trans towards Ser 20. Cell division cycle 25C (CDC25C) phosphorylation by CHK2 is unaffected by the p53 DNA‐binding‐domain peptides. The CHK2‐docking site in the BOX‐V motif is the smallest of the two CHK2 binding sites, and mutating certain amino acids in the BOX‐V peptide prevents CHK2 activation. A database search identified a p53 BOX‐I‐homology motif in p21 WAF1 and although CHK2 is inactive towards this protein, the p53 DNA‐binding‐domain peptides induce phosphorylation of p21 WAF1 at Ser 146. This provides evidence that CHK2 can be activated allosterically towards some substrates by a novel docking interaction, and identify a potential regulatory switch that may channel CHK2 into distinct signalling pathways in vivo .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage.
Lukas, C., Falck, J., Bartkova, J., Bartek, J., & Lukas, J. (2003) · Nature Cell Biology · doi:10.1038/ncb945 · Cited by 474 · cited 1×
“Sequestration of CHK2 to spatially restricted nuclear regions impairs its ability to stimulate p53 activity (Lukas et al., 2003).”
BackgroundThe evolution of diverse biological responses to DNA damage: insights from yeast and p53
Wahl, G. M., & Carr, A. M. (2001) · Nature Cell Biology · doi:10.1038/ncb1201-e277 · Cited by 376
Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions
BIONDI, R. M., & NEBREDA, A. R. (2003) · Biochemical Journal · doi:10.1042/bj20021641 · Cited by 334 · cited 3×
“Such docking sites have been observed previously for CDK2 (Luciani et al., 2000), PDK1, MAPK and GSK3 (Biondi & Nebreda, 2003).”
Background
Cited by
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Role of p53 in Cell Death and Human Cancers
Ozaki, T., & Nakagawara, A. (2011) · Cancers · doi:10.3390/cancers3010994 · Cited by 650
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time
Lukas, J., Lukas, C., & Bartek, J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.006 · Cited by 381
Metadata
- Authors
- Craig, A., Scott, M., Burch, L., Smith, G., Ball, K., & Hupp, T.
- Venue
- EMBO reports
- Published
- 2003-08
- Volume
- 4
- Issue
- 8
- Pages
- 787-792
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W2003842525
- Cited by
- 64
- References
- 4
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. https://app.cochat.ai/papers/10.1038/sj.embor.embor901
- The paper
- Craig, A., Scott, M., Burch, L., Smith, G., Ball, K., & Hupp, T. (2003). Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO reports. https://doi.org/10.1038/sj.embor.embor901
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.